205 related articles for article (PubMed ID: 8788772)
1. Topoisomerase I inhibitors: topotecan and irinotecan.
Jones SF; Burris HA
Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
[No Abstract] [Full Text] [Related]
2. Topoisomerase I inhibitors: topotecan and irenotecan.
Creemers GJ; Lund B; Verweij J
Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
[No Abstract] [Full Text] [Related]
3. Topoisomerase I inhibition: a new target or new missiles?
Verweij J; Schellens JH
Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
[No Abstract] [Full Text] [Related]
4. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials with the topoisomerase I inhibitors.
Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies of camptothecin and derivatives.
Soepenberg O; Sparreboom A; Verweij J
Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
[No Abstract] [Full Text] [Related]
7. Clinical trials using irinotecan.
Houghton PJ; Santana VM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
[No Abstract] [Full Text] [Related]
8. Recent clinical advances with camptothecin analogues.
Slichenmyer WJ; Donehower RC
Cancer Treat Res; 1995; 78():29-43. PubMed ID: 8595145
[No Abstract] [Full Text] [Related]
9. New anticancer agents in clinical development.
Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
Oncology (Williston Park); 1995 Nov; 9(11):1191-9. PubMed ID: 8703688
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
11. [Topoisomerase inhibitors developing in Japan].
Furue H
Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
[TBL] [Abstract][Full Text] [Related]
12. [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
Yang S; Zhang WN
Yao Xue Xue Bao; 2004 May; 39(5):396-400. PubMed ID: 15338888
[No Abstract] [Full Text] [Related]
13. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
14. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase-I inhibitors in the management of colon cancer.
Willson JK
Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
[No Abstract] [Full Text] [Related]
16. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
[TBL] [Abstract][Full Text] [Related]
17. CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.
Bleiberg H
Tumori; 1997; 83(1 Suppl):S85-6. PubMed ID: 9154078
[No Abstract] [Full Text] [Related]
18. Irinotecan hydrochloride.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(4):179-80, 184. PubMed ID: 12690622
[No Abstract] [Full Text] [Related]
19. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
20. [New drugs. Topoisomerase inhibitors].
Gutzler F
Zentralbl Gynakol; 1996; 118(10):579. PubMed ID: 8999716
[No Abstract] [Full Text] [Related]
[Next] [New Search]